The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

Repatha (evolocumab) will be sold in the UK at a cost of $6,780 per year, less than half the $14,100 Amgen is charging for the drug in the US, with the price in other EU markets typically below ...

Repatha (evolocumab) is a brand-name subcutaneous injection that isn’t known to interact with alcohol, other drugs, or supplements. However, Repatha has health-related interactions that are ...

An expensive new drug, evolocumab (Repatha), developed by Amgen, significantly drops cholesterol levels and reduced the risk of major cardiovascular events, researchers reported in a study published ...

[Robinson JG. Clinical Lipid Management;455a] Alirocumab (Praluent, Regeneron) and evolocumab (Repatha, Amgen) are the two mAbs currently approved by the FDA; both received approval in 2015.

Among these PCSK9-targeting therapies is Novartis’s Leqvio (inclisiran), Amgen’s Repatha (evolocumab), and Regeneron’s Praluent (alirocumab). However, none of these therapies offer the single-dose ...

Notable contributors included Repatha (evolocumab) for hypercholesterolemia and hyperlipidemia, Blincyto (blinatumomab) for B-cell acute lymphocytic leukaemia, recently approved in June 2024 ...

Coming back to the first-quarter results, sales of most of its products, like Prolia, Xgeva, Repatha, Blincyto and Evenity, beat estimates. Fourteen products, including Repatha, Blincyto ...